Evidence map›Paper›PMID 37660117›Full record

ArticleSystematic reviews2023

How to update a living systematic review and keep it alive during a pandemic: a practical guide.

Leonie Heron, Diana Buitrago-Garcia, Aziz Mert Ipekci, Rico Baumann, Hira Imeri, Georgia Salanti, Michel Jacques Counotte, Nicola Low

Abstract read
In one paragraph

Article in Systematic reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Informed decisions about public health and social measures.Health research policy and systems · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Leonie HeronInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Diana Buitrago-GarciaInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Aziz Mert IpekciInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Rico BaumannInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Hira ImeriInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Georgia SalantiInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Michel Jacques CounotteWageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands.
Nicola LowInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. nicola.low@unibe.ch.ORCID http://orcid.org/0000-0003-4817-8986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe covid-19 pandemic has highlighted the role of living systematic reviews. The speed of evidence generated during the covid-19 pandemic accentuated the challenges of managing high volumes of research literature.

methodsIn this article, we summarise the characteristics of ongoing living systematic reviews on covid-19, and we follow a life cycle approach to describe key steps in a living systematic review.

resultsWe identified 97 living systematic reviews on covid-19, published up to 7th November 2022, which focused mostly on the effects of pharmacological interventions (n = 46, 47%) or the prevalence of associated conditions or risk factors (n = 30, 31%). The scopes of several reviews overlapped considerably. Most living systematic reviews included both observational and randomised study designs (n = 45, 46%). Only one-third of the reviews has been updated at least once (n = 34, 35%). We address practical aspects of living systematic reviews including how to judge whether to start a living systematic review, methods for study identification and selection, data extraction and evaluation, and give recommendations at each step, drawing from our own experience. We also discuss when it is time to stop and how to publish updates.

conclusionsMethods to improve the efficiency of searching, study selection, and data extraction using machine learning technologies are being developed, their performance and applicability, particularly for reviews based on observational study designs should improve, and ways of publishing living systematic reviews and their updates will continue to evolve. Finally, knowing when to end a living systematic review is as important as knowing when to start.

Indexed as

COVID-19PandemicsSystematic Reviews as TopicHumansMachine LearningObservational Studies as TopicResearch DesignRisk FactorsCovid-19EpidemiologyPublic healthResearch design

Identifiers

PMID37660117
PMCPMC10474670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.